{"title":"Walking the VLDL tightrope in cardiometabolic diseases.","authors":"Mindy Kim, Ze Zheng","doi":"10.1016/j.tem.2024.07.020","DOIUrl":null,"url":null,"abstract":"<p><p>Very-low-density lipoprotein (VLDL), a triglyceride-rich lipoprotein secreted by hepatocytes, is pivotal for supplying peripheral tissues with fatty acids for energy production. As if walking on a tightrope, perturbations in the balance of VLDL metabolism contribute to cardiometabolic dysfunction, promoting pathologies such as cardiovascular disease (CVD) or metabolic dysfunction-associated steatotic liver disease (MASLD). Despite the advent of lipid-lowering therapies, including statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, risks for cardiovascular events persist. With limitations to currently available CVD therapeutics and no US Food and Drug Administration (FDA)-approved treatment for MASLD, this review summarizes the current understanding of VLDL metabolism that sheds light on novel therapeutic avenues to pursue for cardiometabolic disorders.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":11.4000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.tem.2024.07.020","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Very-low-density lipoprotein (VLDL), a triglyceride-rich lipoprotein secreted by hepatocytes, is pivotal for supplying peripheral tissues with fatty acids for energy production. As if walking on a tightrope, perturbations in the balance of VLDL metabolism contribute to cardiometabolic dysfunction, promoting pathologies such as cardiovascular disease (CVD) or metabolic dysfunction-associated steatotic liver disease (MASLD). Despite the advent of lipid-lowering therapies, including statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, risks for cardiovascular events persist. With limitations to currently available CVD therapeutics and no US Food and Drug Administration (FDA)-approved treatment for MASLD, this review summarizes the current understanding of VLDL metabolism that sheds light on novel therapeutic avenues to pursue for cardiometabolic disorders.
期刊介绍：
Trends in Endocrinology and Metabolism (TEM) stands as a premier Reviews journal in the realms of metabolism and endocrinology. Our commitment is reflected in the publication of refined, concise, and highly impactful articles that delve into cutting-edge topics, encompassing basic, translational, and clinical aspects. From state-of-the-art treatments for endocrine diseases to groundbreaking developments in molecular biology, TEM provides comprehensive coverage.
Explore recent advancements in diabetes, endocrine diseases, obesity, neuroendocrinology, immunometabolism, molecular and cellular biology, and a myriad of other areas through our journal.
TEM serves as an invaluable resource for researchers, clinicians, lecturers, teachers, and students. Each monthly issue is anchored by Reviews and Opinion articles, with Reviews meticulously chronicling recent and significant developments, often contributed by leading researchers in specific fields. Opinion articles foster debate and hypotheses. Our shorter pieces include Science & Society, shedding light on issues at the intersection of science, society, and policy; Spotlights, which focus on exciting recent developments in the literature, and single-point hypotheses as Forum articles. We wholeheartedly welcome and encourage responses to previously published TEM content in the form of Letters.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
